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Abstract: Successful infant heart transplantation has now been performed for over 25 years. Assessment of long term 
outcomes is now possible. We report clinical outcomes for322 patients who received their heart transplant during infancy. 
Actuarial graft survival for newborn recipients is 59% at 25 years. Survival has improved in the most recent era. Cardiac 
allograft vasculopathy is the most important late cause of death with an actuarial incidence at 25 years of 35%. Post-
transplant lymphoma is estimated to occur in 20% of infant recipients by25 years. Chronic kidney disease grade 3 or 
worse is present in 31% of survivors. The epidemiology of infant heart transplantation has changed through the years as 
the results for staged repair improved and donor resources remained stagnant. Most centers now employ staged repair for 
hypoplastic left heart syndrome and similar extreme forms of congenital heart disease. Techniques for staged repair, in-
cluding the hybrid procedure, are described. The lack of donors is described with particular note regarding decreased do-
nors due to newer programs for appropriate infant sleep positioning and infant car seats. ABO incompatible donors are a 
newer resource for maximizing donor resources, as is donation after circulatory determination of death and techniques to 
properly utilize more donors by expanding the criteria for what is an acceptable donor. An immunological advantage for 
the youngest recipients has long been postulated, and evaluation of this phenomenon may provide clues to the develop-
ment of accommodation and/or tolerance. 
Keywords: Clinical outcome, congenital heart disease, donor issues, infant heart transplant, hypoplastic left heart syndrome, 
indications for transplant. 
HISTORICAL PERSPECTIVE 
  Infant heart transplantation was first attempted by Adrian 
Kantrowitz 3 days after Christiaan Barnard’s famous first 
transplant performed in 1967. Magdi Yacoub in London per-
formed a heart transplant on a 10-day-old baby in 1984. The 
infant survived 18 days. In the fall of the same year, Leonard 
Bailey and the team at Loma Linda University performed a 
xenotransplant operation, inserting the heart of a baboon into 
a 12-day-old baby who survived 20 days. The first successful 
infant recipient was transplanted by Denton Cooley in 1984 
and this child survived 13 years. The first successful new-
born heart recipient was transplanted at Loma Linda in 1985 
at the age of 4 days. He is still alive and well, with his first 
graft, 25 years later
 [1]. 
  There have been 8575 pediatric heart transplant proce-
dures reported to the International Society for Heart and 
Lung Transplantation Registry through 2009 [2]. Of these, 
2171 (25%) have been performed in infants. The number of 
infant heart transplants reported per year has remained rela-
tively stable over the last decade at approximately 100 pro-
cedures per year. Over the years, though, the proportion of 
transplant procedures performed for infants with a diagnosis 
of congenital heart disease has changed from 80% of the to-
tal in 1988-1995 to 63% from 1996-2009 [3]. 
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  In the last quarter century, much has been learned about 
infant heart transplantation. But, much remains to be discov-
ered. This report will describe the clinical outcome of infant 
heart transplant recipients, utilizing the Loma Linda experi-
ence, concentrating on survival, rejection, cardiac allograft 
vasculopathy, post-transplant lymphoproliferative disease 
and long-term renal function. In addition, we will describe 
issues that are especially pertinent to infant heart transplanta-
tion; donor availability, ABO incompatible transplantation, 
surgical management of infants with hypoplastic left heart 
syndrome (HLHS) and similar extreme forms of congenital 
heart disease, and transplantation and the hybrid procedure 
for palliation of HLHS. 
CLINICAL OUTCOME OF INFANT HEART TRANS-
PLANTATION – THE LOMA LINDA EXPERIENCE: 
  There have been 322 infant heart transplant procedures 
performed at Loma Linda University Children’s Hospital 
from November 1985 through November 2010. Of these, 
103 or 32 % were performed during the first month of life, 
with the youngest transplanted at 1.5 hours of life [4]. Early 
in the experience, the indication for the vast majority of 
these transplants was HLHS. Because of limited donor avail-
ability, most newborns with HLHS now receive staged sur-
gical repair. Fig. 1 illustrates the number of transplant proce-
dures in newborns (0-30 days) and infants (1-12 months) by 
year. One can see that the proportion of newborns trans-
planted has declined, illustrating the change in donor avail-
ability over time. Heart Transplantation for Congenital Heart Disease in the First Year of Life  Current Cardiology Reviews, 2011, Vol. 7, No. 2    73 
  The actuarial survival for these patients is illustrated in 
Fig. 2. Newborn recipients have better survival than those 
transplanted later in infancy. The reason for this is probably 
multi-factorial and likely includes an immunological advan-
tage to early transplant (discussed below) and avoidance of 
complications that arise with prolonged waiting time. The 
graft half-life for newborn recipients is still undefined, with 
an actuarial graft survival at 25 years of 59%, likely the 
longest graft half-life for any solid organ transplant popula-
tion. 
  There has been an era effect similar to effects reported in 
the ISHLT registry report. This is illustrated in Fig. 3. 
  The causes of death are similar to what one might expect, 
with acute and chronic rejection (i.e. cardiac allograft vascu-
lopathy - or CAV) being the most significant [5]. Acute re-
jection accounted for 16% of deaths, acute rejection with ac-
companying CAV accounted for 8% of deaths, and CAV 
alone accounted for 14% of deaths. Acute graft dysfunction 
was only present in 5 infant recipients. Infection caused 16% 
of deaths and neoplasms, most commonly post-transplant 
lymphoproliferative disease, accounted for 9% of deaths.  
  Our immunosuppression regimen has evolved over the 
years, but it has consistently had the goal of steroid avoid-
ance. Less than 5% of our infant recipients require mainte-
nance steroids to prevent rejection. Similar shorter term out-
comes have recently been demonstrated by the Boston Chil-
dren's group [6]. Our current protocol is included in the Ap-
pendix. 
  Acute rejection late after infant heart transplantation oc-
curs, as illustrated by Fig. 4. Between 10 and 20 years after 
infant heart transplantation approximately 30% of patients 
will experience a rejection episode. There is a particular haz-
ard of rejection during adolescence when issues of non-
adherence become more important. 
  Consistent with other reports, [3] cardiac allograft vascu-
lopathy is the greatest barrier to long-term graft and patient 
survival. The ISHLT registry report notes that the 10 year 
freedom from CAV in the infant population was 73%. They 
also note that not being on steroids at the time of discharge 
may decrease the risk of CAV (RR 0.61; p=0.07). It is possi-
ble that our steroid avoidance regimen contributes to our 10 
year freedom from CAV rate of 82%. The 25 year actuarial 
freedom from CAV in our infant population is illustrated in 
Fig. 5. 
  Post-transplant lymphoproliferative disease (PTLD) is 
another important cause of late morbidity and mortality. In a 
multi-center report [7], the probability of PTLD was reported 
as 8% at 5 years post-transplant. A single center report [8] 
described an actuarial risk of PTLD at 10 years at 28%. In 
our infant population we have seen a 22% actuarial risk of 
PTLD at 25 years after transplant (see Fig. 6). Interestingly, 
the time to infection parallels the risk of PTLD with essen-
tially all infant recipients predicted to have been infected by 
Ebstein Barr Virus (EBV) by 19 years after transplant. (Also 
see Fig. 6) 
  Long-term renal function is a particular concern in a 
population that is hoped to survive for decades after trans-
plant. It is a particular concern in the infant population since 
they are transplanted before kidney maturity has occurred. 
Of those infants who have survived at least 10 years, 47% 
are receiving anti-hypertension therapy. We have also under-
taken a program of thorough evaluation of renal function, 
performing an isotopic glomerular filtration rate (i-GFR) on 
an annual basis on all patients followed at our institution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Number of patients transplanted in each year, categorized by Newborn (First 30 days) or Infant (31-365 days). 74    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Chinnock and Bailey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Actuarial graft survival. Log rank p=0.027 for 0-30 day old recipients versus 1-3 month old recipients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Graft Survival by Era of Transplant. (Kaplan-Meier analysis; p=0.02 by log rank). 
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Fig. (4). Freedom from rejection starting at 10 years after transplantation. N=265. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Freedom from cardiac allograft vasculopathy (CAV) by age at transplant. Newborn = 0-30 days, Infant = 31-365 days. No statistical 
significant difference, p=0.495 by log rank test. 
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Fig. (6). Actuarial freedom from PTLD after infant heart transplantation (solid line); Earliest evidence of infection (either by serology or Po-
lymerase Chain Reaction) with EBV (dotted line). 
 
The most recent i-GFR for 93 infant recipients who have 
survived at least 10 years is noted in Fig. 7. The average i-
GFR in these patients is 73 mL/min/1.73m
2. However, there 
are a significant number of patients with significant renal in-
sufficiency and 7 infants have received renal replacement 
therapy late after heart transplantation. The number of pa-
tients in each category of chronic kidney disease (as defined 
solely by their GFR) is illustrated in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Most recent i-GFR represented, each dot represents an in-
dividual patient. Upper and lower limits of normal (dotted line); 
trend line (solid line). 
CLINICAL ISSUES IN INFANT HEART TRANS-
PLANTATION 
  There is now a 25 year history of successful infant heart 
transplantation. Much has been learned, but much remains to 
be understood. The following will describe those issues most 
applicable to infant heart transplantation: 
•  Which congenital heart lesions should be managed with 
heart transplantation as primary therapy, if any? 
•  What is the optimal approach to hypoplastic left heart 
syndrome and equivalent malformations? 
•  How might the supply of donors be improved? 
•  Is there an immunologic advantage for the younger re-
cipient? 
Surgical Management of Infants with Hypoplastic Left 
Heart Syndrome and Similar Extreme Forms of Con-
genital Heart Disease 
  Hypoplastic left heart syndrome (HLHS) was once con-
sidered beyond surgical relief. Infants born with it, died be-
cause of it. During the past quarter-century, however, the 
story has dramatically improved. Norwood’s staged-
reconstruction and infant heart transplantation grew out of 
the early 1980’s to create a positive change in survival for 
infants with this and similar extreme forms of congenital 
heart disease [9, 10]. Neither treatment pathway threatened 
development of the other. The need for effective and repro-
ducible therapy was just too great. Oddly enough, it was a 
significant early difference in operative survival that gave 
both strategies momentum. During the 1980’s and early 
1990’s, survival following transplantation was the rule, 
whereas survival was more the exception after Norwood’s 
procedure. This differential in outcomes not only served to 
establish transplantation as an important, if limited, option, 
but it encouraged Norwood and a handful of other skillful 
and committed surgical teams toward improved infant sur-
vival following palliative-reconstruction. Eventually, donor 
offers plateaued (never more than about 100 annually in 
North America), and survival following reconstruction be-
came remarkably competitive [11-13]. By the mid to late 
1990’s, virtually every center, Loma Linda included, had   
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shifted to Norwood’s strategy as primary therapy for HLHS 
and equivalent cardiac anomalies. Heart transplantation, be-
cause of donor limitations, became consigned, as primary 
therapy, to those very few infants deemed unsuitable for 
staged-reconstruction. Primary transplantation has remained 
available in some centers as a parental choice, and as the 
only solution for the occasional young infant with profound 
cardiomyopathic disease, including some tumors. 
  Both understanding and application of Norwood’s 
staged-reconstruction has evolved brilliantly during the past 
two decades. The approach now includes three separate 
stages. The first, and most challenging stage is accomplished 
in the neonate. It involves aortic arch reconstruction (usually 
with pulmonary allograft tissue) and uses the native pulmo-
nary valve for systemic ventricular outflow. The pulmonary 
circulation is separated from the heart and is driven by 
means of a modified Blalock-Taussig shunt (Fig 8-A). Alter-
natively, a polytetrafluoroethylene (PTFE) tube is used to 
connect the base of the ventricle to the branch pulmonary 
arteries, a modification introduced by Sano and colleagues 
(Fig. 8-B) [14]. The atrial septum is excised. 
  As many as 9 out of 10 neonates now survive Norwood’s 
first stage of reconstruction. Survival following stage-one 
reconstruction appears to be independent of the source of 
pulmonary blood flow; i.e., Blalock-Taussig shunt vs. Sano 
conduit, but many believe that perioperative management is 
less stressful for infants who have Sano’s modification. 
While there remains some interstage attrition, the vast major-
ity of these babies reach consideration for a second stage 
procedure. 
  The second stage of reconstruction is applied between 
four and eight months of age and requires adequate preopera-
tive physiology in the form of low pulmonary pressure and 
resistence, good ventricular and atrioventricular valve func-
tion. Stage-two varies depending upon the projected form the 
final Fontan stage will take. If an intra-atrial lateral tunnel or 
if a catheter-based completion of the Fontan circuit is antici-
pated, then stage-two reconstruction usually consists of a so-
called “hemi-Fontan” procedure. This involves interruption 
or takedown of the first-stage source of pulmonary blood 
flow and creation of bidirectional superior vena caval-to-
pulmonary artery flow that incorporates the superior pole of 
the right atrium. The atrial cavity is separated from the pul-
monary circulation by means of a thin baffle of tissue or 
PTFE. This sets the stage for intra-atrial lateral tunnel Fontan 
completion. If catheter-based completion is anticipated, a 
short circular tube of PTFE is sutured around the inferior 
vena caval entrance to the atrium. This becomes an attach-
ment site for a covered stent extending from the inferior vena 
cava to the pulmonary artery. Alternatively, the second stage 
procedure is nothing more than takedown of the previous 
source of pulmonary blood flow and creation of a bidirec-
tional cavopulmonary (Glenn) anastomosis (Fig. 9). This is 
the procedure used at Loma Linda. Any additional aortic 
arch reconstruction or atrioseptectomy is accomplished at the 
second stage. 
  Timing of the final or third stage varies depending upon 
the anticipated type of Fontan completion. Many centers, in-
cluding Loma Linda, complete the final stage of reconstruc-
tion between 18 and 24 months of age. A pedicled tube of 
autologous pericardium is utilized for extracardiac Fontan 
completion at Loma Linda (Fig. 10) [15].  
  Those centers using an extra-cardiac prosthetic conduit 
may choose to delay the final stage to age three or four in an 
effort to accommodate a larger inferior vena cava-to-
pulmonary artery conduit (Fig. 11).  
  An infant with a hemi-Fontan circuit will have an intra-
atrial lateral tunnel constructed of PTFE. The stage-two baf-
fle separating the pulmonary circuit from the atrium is, of 
course, excised. The issue of routine fenestration in the Fon-
tan circulation remains open to debate. Fenestration has 
rarely been employed in the Loma Linda experience. Cathe-
ter-based completion of the Fontan circuit has, thus far, 
failed to gain traction for lack of appropriate devices. 
  While outcomes of staged reconstruction in the present 
era have become truly spectacular in experienced centers, 
still a few infants and children fail to respond satisfactorily 
[16]. Transplantation has occasionally become necessary, 
and this has occurred after each stage. Ventilator-dependence 
has become an issue after stage-one, and poor ventricular 
function, atrioventricular valve regurgitation, and pulmonary 
arteriovenous fistulae are the issues after stages two and 
three. Protein-losing enteropathy is an indication for heart 
transplantation that is unique to stage-three Fontan circula-
tion. 
  In the current era, therefore, transplantation has become 
secondary or salvage therapy for somewhat older infants and 
children who have failed to progress through staged-
reconstruction or who are failing Fontan’s physiology. In 
Table 1.  Distribution of Patients by Chronic Kidney Disease Category. 
Chronic Kidney Disease Category  i-GFR mL/min/1.73m
2 Number  of  Patients 
1 >=90  22  (24%) 
2 60-89  42  (45%) 
3 30-59  23  (25%) 
4 15-29  6  (6%) 
5 <15  0  (0%) 
 Total  93  (100%) 78    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Chinnock and Bailey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). A/B. Norwood’s procedure for hypoplastic left heart syndrome and equivalent malformations. (A) The classic procedure using a 
modified Blalock-Taussig shunt, and (B) the Sano modification using a conduit from ventricle to pulmonary arteries. Ao=aorta. IVC=inferior 
vena cava. LPA=left pulmonary artery. PV=pulmonary valve. PA=pulmonary artery. RPA=right pulmonary artery. RV=right ventricle. 
SVC=superior vena cava. TV=tricuspid valve. Barron DJ, Kilby MD, Davies B, Wright JGC, Jones TJ, Brawn WJ. Hypoplastic left heart 
syndrome. Lancet 2009; 374:551-64. Used with permission of the publisher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Cavopulmonary (Glenn) anastomosis – the second stage of palliative reconstruction. Ao=aorta. IVC=inferior vena cava. LPA=left 
pulmonary artery. PV=pulmonary valve. RPA=right pulmonary artery. RV=right ventricle. SVC=superior vena cava. TV=tricuspid valve. 
Barron DJ, Kilby MD, Davies B, Wright JGC, Jones TJ, Brawn WJ. Hypoplastic left heart syndrome. Lancet 2009; 374:551-64. Used with 
permission of the publisher. Heart Transplantation for Congenital Heart Disease in the First Year of Life  Current Cardiology Reviews, 2011, Vol. 7, No. 2    79 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). The Fontan completion as accomplished at Loma Linda University Children’s Hospital. A-C, surgical technique. An extracardiac 
tunnel is fashioned from in situ (pedicled) autologous pericardium. ECLT=extracardiac lateral tunnel, RA=right atrium. Hasaniya NW, Raz-
zouk AJ, Mulla NF, Larsen RL. In situ pericardial extracardiac lateral tunnel Fontan operation: Fifteen-year experience. J Thorac Cardiovasc Surg 
2010; 140: 1076-83. Used with permission of the publisher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (11). Total cavopulmonary connection – the stage-three Fontan completion. An extracardiac prosthetic conduit is utilized to carry inferior 
vena caval flow to the pulmonary arteries. Ao=aorta. IVC=inferior vena cava. LPA=left pulmonary artery. RPA=right pulmonary artery. 
RV=right ventricle. SVC=superior vena cava. TV=tricuspid valve. Barron DJ, Kilby MD, Davies B, Wright JGC, Jones TJ, Brawn WJ. Hy-
poplastic left heart syndrome. Lancet 2009; 374: 551-64. Used with permission of the publisher. 80    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Chinnock and Bailey 
addition, infants and children with congenital heart anoma-
lies who have experienced a variety of surgical or catheter-
based interventions ending in systemic or bi-ventricular fail-
ure, arrive at transplantation, not infrequently, by means of 
mechanical circulatory assistance. Transplantation in this 
“back-up” role for treatment of congenital heart disease has 
produced less impressive operative and late survival, particu-
larly among children who are failing Fontan’s physiology or 
who have become older following palliative therapy [17-20]. 
The reasons for reduced transplant operative survival seems 
apparent, as the poor general status of potential recipients 
and as the complexities of transplant-reconstruction are con-
sidered. Reduced late post-transplant survival usually relates 
to pre-transplant recipient sensitization, and hence, to the 
presence of graft-specific allo-antibodies [21, 22]. 
Transplantation and the Hybrid Procedure for Palliation 
of Hypoplastic Left Heart Syndrome 
  A more recent innovation in the management of HLHS is 
the so-called hybrid approach. It consists of bilateral pulmo-
nary artery banding, accomplished surgically via sternotomy, 
with either simultaneous or delayed catheter-based stenting 
of the patent ductus arteriosus. This is coupled with balloon 
atrioseptostomy (Fig. 12).  
  This approach has received considerable attention in Co-
lumbus, Ohio [23] and among a few other centers with hy-
brid laboratories which are designed to permit simultaneous 
high-resolution imaging, cardiac catheterization, and cardiac 
surgery [24, 25]. While the approach has produced reason-
able outcomes, it has been slow to “catch-on,” perhaps be-
cause it requires careful patient selection and considerable 
operator experience to compete with outcomes following the 
now “standard” stage-one Norwood procedure. In addition, it 
adds important complexity to the second stage of reconstruc-
tion. This hybrid form of palliation may, however, have a 
place in stabilizing the neonate with HLHS who is on a 
transplant trajectory, and whose wait for a donor heart is pro-
longed. Removal of the ductal stent and augmentation of the 
branch pulmonary arteries should add little to a transplant 
procedure. This sequence has not yet been accomplished at 
Loma Linda. The Loma Linda group has, however, em-
ployed ductal stenting alone for temporary palliation on five 
occasions. Four of these infants experienced successful 
transplantation. Indeed, any discussion of hybrid palliation 
as bridge to transplantation remains interesting, but specula-
tive. 
Donor Issues 
  Infants awaiting heart transplantation face the highest 
waiting list mortality of any age group listed for heart trans-
plantation [26]. Approximately 1 in 4 infants will die while 
waiting, with highest mortality in infants < 3 kg, those on 
extracorporeal membrane oxygenation or ventilator support, 
requirement for prostaglandin, those with congenital heart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). Hybrid procedure, an alternate approach to the first-stage Norwood operation. The hybrid procedure consists of surgically applying 
branch pulmonary artery bands and catheter-based application of a stent in the arterial duct. A balloon atrioseptostomy or insertion of an atri-
oseptal stent is also accomplished. Barron DJ, Kilby MD, Davies B, Wright JGC, Jones TJ, Brawn WJ. Hypoplastic left heart syndrome. 
Lancet 2009;374:551-64. Used with permission of the publisher. Heart Transplantation for Congenital Heart Disease in the First Year of Life  Current Cardiology Reviews, 2011, Vol. 7, No. 2    81 
disease for which alternate surgical palliation was not per-
formed and non-white race/ethnicity [27]. An adequate do-
nor supply, therefore, is one of the most important issues af-
fecting overall mortality and has long been an issue for in-
fant heart transplantation [28]. Indeed, the lack of a suitable 
donor was part of the rationale for using a baboon donor in 
1984 [29]. 
  Two relatively recent public health efforts, i.e. changes in 
sleep position to reduce sudden infant death syndrome 
(SIDS) [30] and mandatory infant car seats have potentially 
affected the number of donors from these sources. Child 
safety seats reduce the risk of death in passenger cars by 
71% for infants, and by 54% for toddlers ages 1 to 4 years 
[31]. It is possible that this has affected the availability of 
donors suitable for infants, but this has not been evaluated to 
date. 
  The incidence of SIDS has been dramatically reduced in 
the last 15 years [30]. Still, SIDS is the third leading cause of 
death for infants with an estimated annual incidence in the 
United States of 0.54 per 1,000 live births [32]. There have 
been concerns regarding the use of donor hearts from infants 
with SIDS because of the uncertainty whether the cause of 
death may be cardiac in origin and then subsequently mani-
fest itself in the recipient. A recent retrospective report utiliz-
ing data from the Unites States Organ Procurement Trans-
plant Network data did not demonstrate a difference in clini-
cal outcome between infants transplanted with a donor who 
died from SIDS versus donors who died of other causes. In-
terestingly, they also noted that proportion of transplanted 
infant donor hearts where that donor cause of death was 
SIDS has increased from just over 4% in 2000-02 to nearly 
9% in 2006-08. This is likely due to transplant centers’ in-
creasing confidence with the use of SIDS donors. 
  Cardiac transplantation in infancy using ABO incompati-
ble donors in the appropriate setting [33] has now become an 
established protocol in many centers around the world. Out-
comes for infants who receive an ABO incompatible donor 
are equivalent to those who receive a compatible donor [34, 
35]. A strategy utilizing listing for ABO incompatible dona-
tion is associated with a higher likelihood of transplantation 
within 30 days for infants with blood group O [36]. Infants, 
and even some toddlers, transplanted using this protocol do 
not develop isohemagglutinin reactions to the “incompati-
ble” donor blood group antigen. Interestingly, and also po-
tentially very importantly, infants and young children trans-
planted with an ABO-incompatible graft have been shown to 
have a reduced development of antibodies specific for class 
II HLA, including donor specific antibodies [37]. ABO-
incompatible transplantation appears “non-inferior” to ABO 
compatible transplantation, and in fact may have important 
immunologic advantages. 
  Donation after Circulatory Determination of Death 
(DCDD) has potential to impact the donor supply [38]. In a 
recent study, 4.3% of patients in a Neonatal Intensive Care 
Unit who were withdrawn from life support would have been 
suitable heart donors after circulatory determination of death 
[39]. This practice, however, has significant ethical and legal 
implications [40]. Currently it seems most prudent for any 
program using a DCDD process to do so only under the aus-
pices of an Institutional Review Board protocol. 
  A more fruitful source of potential donors might be those 
potential donors who are not used for transplantation. Be-
tween 2000 and 2008, nearly 35% of pediatric donors in the 
UNOS database were not used for transplantation. It is pos-
sible that the smaller recipient pool could make it likely that 
there wouldn’t be a suitable recipient for every given donor. 
However, there are many donors turned down for reasons of 
presumed unsuitability of the graft. A series of 29 pediatric 
heart transplant procedures, utilizing grafts that had been 
turned down because of presumed graft unsuitability, was 
shown – even in the face of prolonged ischemic time – to not 
affect transplant survival [41]. 
  Increasing the donor pool is in many ways more impor-
tant than what occurs after transplant, for the mortality prior 
to transplantation in infants is higher than one year mortality 
after transplantation. It appears that routine listing for ABO-
incompatible donation in the appropriate setting and a will-
ingness to consider donors that appear to be unsuitable 
should be routine practice in pediatric heart transplant cen-
ters. 
Immunological Advantage for Younger Recipients? 
  One of the earliest experiments in transplantation, con-
ducted by Billingham and Medawar [42]. demonstrated that 
exposure of the neonatal mouse to alloantigens induced per-
manent and specific abrogation of immune responsiveness to 
those antigens. This so-called neonatal “window of opportu-
nity” continues to intrigue immunologists, but it is still un-
known how clear or opaque a window this is. 
  The immune reaction to allotransplantation has been de-
scribed as universal, rapid and severely destructive [43]. 
And, in the absence of immunosuppression, even newborn 
recipients may react to their graft in this fashion. Still, there 
appears to be an advantage to newborn transplantation. Our 
experience is that newborn recipients have better survival, 
less rejection and less cardiac allograft vasculopathy as illus-
trated in Figs 2, 4 and 5. Newborn “tolerance” is probably 
multi-factorial, and has been the subject of many theories. Is 
there negative selection, as occurs in natural self-tolerance? 
[44] Or, is the newborn immune system less capable of pre-
senting antigens because of decreased expression of major 
histocompatibility complex (MHC) class II antigens [45]. 
What we do know is that delivery of blood group antigens 
early in life can induce tolerance specific to isohemaggluti-
nins [46]. This occurs by elimination of donor-reactive B 
lymphocytes and depends upon a continued expression of 
antigen. 
  The infant who has undergone heart transplantation, with 
concomitant removal of the thymus, may provide important 
clues to the interplay between the thymus and immunosup-
pression in the immature human. The T-cell receptor diver-
sity in the blood of infants who undergo heart transplantation 
during infancy has been shown to be markedly diminished. 
The normal person has approximately one billion different T 
cells. Some infant heart transplant recipients have as few as 
1000. In addition, thymic function, as deduced from levels of 
human herpesvirus 7 was notably impaired [47]. 
  There has been an increased risk of infections in infant 
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Interestingly, an increased risk of autoimmune disease was 
also noted [48]. 
  The infant heart transplant recipient is likely to provide 
important clues to the development of accommodation 
and/or tolerance, and they should be studied with increased 
vigor. 
CONCLUSION 
  Heart transplantation during infancy has now been suc-
cessfully performed for 25 years. Much has been learned, but 
much remains to be learned. Since a lifespan after infant 
heart transplantation is potentially much longer than for an 
adult recipient, it is imperative to more aggressively pursue 
methods to prevent and treat those long-term morbidities 
most likely to impact longevity – cardiac allograft vasculo-
pathy, post-transplant lymphoproliferative disease, and long-
term kidney function. Not noted in this review, but addressed 
elsewhere in this issue of the journal, is the challenge of non-
adherence, particularly during adolescence. 
  Surgical techniques have been refined, and the debate 
about staged repair versus transplantation for HLHS and 
equivalent lesions has, because of improved results with 
staged repair and continued lack of sufficient numbers of 
suitable donors, been settled in favor of staged repair. Trans-
plantation as primary therapy is now reserved for patients 
with severe valve regurgitation and/or significantly impaired 
ventricular function. Many of these patients, however, will 
come to transplantation after any of the repair stages. And, 
these patients, because of chronic illness and increased anti-
donor antibodies, are more challenging to transplant. 
  The lack of suitable donors continues to limit the full ex-
pression of what could be superior therapy for many infants. 
Salutary public health initiatives, such as the change in infant 
sleep positions and mandatory infant car seats, have de-
Appendix 
Pediatric Cardiac Transplant Immunosuppression 
 
Intra-Operatively 
Cyclosporine IV (0.5 mg/kg/hr) or 
Tacrolimus SL 0.1 mg/kg/day divided Q8-12h (for high risk patients, e.g. High PRA, 
African-American recipient, re-transplantation) 
 
Post-Operatively 
IVIG 400 mg/kg/dose QDay x 5 doses 
Thymoglobulin IV 1.5 mg/kg/dose Qday x 5 doses (>30 days of age) 
Methylprednisolone IV 20 mg/kg/dose Q12h x 4 doses 
Mycophenolate mofetil IV 30mg/kg/dose Q12h (switch to PO when able to take oral) 
Cyclosporine IV 0.5 mg/kg/hr (switch to PO when able to take oral) or  
Tacrolimus SL 0.1mg/kg/day divided Q8-12h (switch to PO when able to take oral) 
 
Maintenance (0-120 Days) 
Cyclosporine PO 3-15 mg/kg/day divided Q8-12h or  
Tacrolimus PO 0.1-0.2 mg/kg/day divided Q8-12h 
Plus 
Mycophenolate mofetil PO 20-30 mg/kg/dose Q8-12h or 
Azathioprine PO 3 mg/kg/dose Q24h (for MMF intolerant patients) 
 
Maintenance (121-365 Days) 
Cyclosporine PO 3-15 mg/kg/day divided Q8-12h or  
Tacrolimus PO 0.1-0.2 mg/kg/day divided Q8-12h 
Plus 
Sirolimus PO 1 mg/m
2 /day Q12-24h or 
Everolimus PO 0.25-1.5 mg Q12h 
 
Maintenance (>365 Days) 
Tacrolimus PO 0.1-0.2 mg/kg/day divided Q8-12h 
Plus 
Sirolimus PO 1 mg/m
2 /day Q12-24h or 
Everolimus PO 0.25-1.5 mg Q12h 
 
 
Cyclosporine Target Levels 
0-3 months 250-300 ng/mL 
4-6 months 150-200 ng/mL 
7-9 months 100-150 ng/mL 
10-12 months 75-100 ng/mL 
>12 months = Switch to Tacrolimus 
Tacrolimus Target Levels 
0-3 months 12-15 ng/mL 
4-6 months 8-10 ng/mL 
7-9 months 6-8 ng/mL 
9-12 months 5-6 ng/mL 
>12 months 4-5 ng/mL 
Sirolimus Target Levels 
4-6 months 8-10 ng/mL 
7-9 months 6-8 ng/mL 
9-12 months 5-6 ng/mL 
>12 months 4-5 ng/mL 
Everolimus Target Levels 
4-12 months 5-8 ng/mL 
>12 months 3-5 ng/mL 
Mycophenolic Acid Target Level 
0-3 months 2-5 ng/mL Heart Transplantation for Congenital Heart Disease in the First Year of Life  Current Cardiology Reviews, 2011, Vol. 7, No. 2    83 
creased the number of suitable donors. But, there are still 
many donors who are not used due to concerns, which may 
not be valid, regarding their suitability for transplantation. 
  Lastly, there is an apparent survival advantage for the 
youngest recipients. The graft half-life for newborn heart 
transplant recipients is still undetermined even 25 years later. 
Part of this advantage appears to be immunological. Trans-
plantation for infants in the setting of ABO-incompatibility 
is possible because of their lack of pre-existing isohemagglu-
tins, and leads to tolerance for the “incompatible” antigen. A 
preliminary picture is developing of the changes that occur 
in infants who are transplanted early in life, and who have 
removal of the thymus and then introduction of T-cell de-
pleting agents and immunosuppression. But, there is still a 
conspicuous lack of understanding of just what might be 
other immunological factors involved in the so-called “neo-
natal window of opportunity”. 
  Apart from the more widespread introduction of safer 
mechanical assist devices in this population, it is unlikely 
that major changes will occur in surgical management. The 
current frontier for infant heart transplantation will be in the 
management of the sensitized recipient, improved prevention 
and management of long-term complications, and a better 
understanding of the immunologic milieu. 
ABBREVIATIONS 
CAV  =  Cardiac Allograft Vasculopathy 
DCDD  =  Donation after Circulatory Determination 
of Death 
EBV =  Epstein  Barr  Virus 
HLHS  =  Hypoplastic Left Heart Syndrome 
i-GFR  =  Isotopic Glomerular Filtration Rate 
ISHLT  =  International Society for Heart and Lung 
Transplantation 
PTLD = Post-Transplant  Lymphoproliferative  Dis-
ease 
SIDS  =  Sudden Infant Death Syndrome 
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